Clerk of the House of Representatives Legislative Resource Cepter B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

DECHETARY OF THE SENATE

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

l. Registrant Name Novartis	
2. Address : Check if different than previously reported. 701 Pennsylvania Ave. NW Washington Suite 725 DC 20064	
Printipal Place of Business (if different from line 2)	
City State/Zip (or Country)	
4. Contact Name Telephone E-mai Rachel King 202-638-7429	1 (optional) 5. Senate 3D 6 9264-12
7. Client Name Self Novartis Corporation	6. House #3# 33589800
 Check if this filing amends a previously filed version of thi Check if this is a Termination Report	n Date 11. No Lobbying Activity
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 🖂	Less than \$10,000 []
\$10,000 or more	\$10,000 or more SI >> \$ \frac{\$1,460,000.00}{\text{Expenses (newest \$20,000)}}\$ 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.
(including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	☐ Method A. Reporting amounts using LDA definitions only ☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
2	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
Signature fell Oly	Date 8/11/00
Printed Name and Title Rachel King - Vice President	Page 1 of 20

Registrant Name:	Novartis		
lient Name:	Novartis Corporation		
ngaged in lobbyir		ry to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provide sd.	
5. General issue	area code AGR (one per page)	}	
 Specific Lobb S.1464, , H.R.1592, , 	ying issnes		
Department	ongress and Federal agencies contacted of Agriculture at Protection Agency resentatives	Check if None	
8. Name of each	individual who acted as a lobbyist in this Name	s issue area Covered Official Position (if applicable)	New
Muldoos, Jo			No
-			
	··		

10 Interset of an	h foreign entity in the specific issues liste To the degree that public policies, cithe AG, as its parent, will benefit.	ed on line 16 above	oration, sc
Nevartis AG	,,, , ,		
Nevartis AG 100 Novartis		Date	
Nevartis AC too Novartis		Date 8/11/90 Page	

cnt ?	lame:	Novartis	Corporation				·········		
m	Descrip	tion		Data					
	Lobbyin	g Issues		59 Fed. Reg. Initiation of S Food Quality Insect Resists Genetically E	50412 (11/24/9 Special Review Protection Ac more Managem ngineered Cro Appropriations	í ent ps		nazine: Not	ice of
	İ								
rone			A I I CENSUSTRIN	O41 171		V 15 · · · · · · · · · · · · · · · · · ·	TATE OF THE PROPERTY OF THE PR		· THE II-EIGENAMANAHAMA
									Page 3 of 20

Registrant Name:	Novartis		
Client Name:	Novartis Corporatina		
engaged in lobbyin	ig on behalf of the client during the report sested. Attach additional page(s) as neede		
 General issue Specific Lobi 		,	
16. Specific Looi	And trans		
	,		
17. House(s) of (Ongress and Federal agencies contacted	₩ Check if None	
18. Name of cach	individual who acted as a lobbyist in this	issue area	
	Name	Covered Official Position (if applicable)	New
······································			
	·		
		i	
	th (breign entity in the specific issues liste		
19. Interest of ea	th foreign entity in the specific issues liste	ed on line 16 above 图 Check if None	
19. Interest of ear	th foreign entity in the specific issues liste	ed on line 16 above M Check if None Date 8/11/00	
19. Interest of ear	ch foreign entity in the specific issues liste	ed on line 16 above 图 Check if None	e 4 of 20

Registrant Name:	Novartis	······	
Client Name:	Novartis Corporation		
engaged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide i.	
 General issue Specific Lobb Appropriation Administration 	ying issues		
17. House(s) of C House of Rep Senate	ongress and Federal agencies contacted resentatives	Check if None	
18. Name of each	individual who acted as a lobbyist in this i	issue area Covered Official Position (if applicable)	New
**************************************		-	
Elkin, James			No
	lehorah	·	
Dusseasgn, 1	<u>Octorah</u>		No
bussiasga, 1	Deborah		
19. Interest of eac	h foreign entity in the specific issues listed	I on line 16 above	No
19. Interest of eac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit,		No
19. Interest of eac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit,	r laws or regulations, commercially benefit Novartis Corpo	No No ration, so

lient Name:	Novartis Corporation		
ngaged in lobbyin		o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide	
 General issue 	area code CAW (one per page)		
Specific Lobb	ying issues		
7. House(s) of C	ongress and Federal agencies contacted	M Check if None	
		•	
8. Name of each	individual who acted as a lubbyist in this iss	ue area	
8. Name of each	individual who acted as a lubbyist in this iss		New
8. Name of each		tie area Covered Official Position (If applicable)	New
8. Name of each			New
8. Name of each			New
8. Name of each			New
8. Name of each			New
8. Name of each			New
8. Name of each			New
8. Name of each			New
8. Name of each			New
8. Name of each			New
	Norne	Covered Official Position (If applicable)	New
		Covered Official Position (If applicable)	New
	Norne	Covered Official Position (If applicable)	New
	Norne	Covered Official Position (If applicable)	New
9. Interest of each	h foreign entity in the specific issues listed o	Covered Official Position (If applicable)	New
9. Interest of each	Norne	Covered Official Position (If applicable)	New

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
ngaged in lobbyi nformation as req	g on behalf of the client during the reporting sested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant g period. Using a separate page for each code, provide	
 General issue Specific Lobi Food Quality 			
Department Environmen	Congress and Pederal agencies contacted of Agriculture all Protection Agency Administration presentatives	☐ Check if None	
8. Name of each	individual who acted as a lobbyist in this is	issue area . Covered Official Position (if applicable)	New
	Name	·	
Name of each	Name	·	Now No
	Name	·	
	Name	Covered Official Position (if applicable)	No
	Name	·	No
	Name	Covered Official Position (if applicable)	No
	Name	Covered Official Position (if applicable)	No
	Name	Covered Official Position (if applicable)	No
Multionn, Jo Multionn, Jo Interest of ea. Novartis AG too Novartis	th foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit,	on line 16 above	No
Multioga, Jo Interest of ear Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit.	Covered Official Position (if applicable) Label Check if None	No No noration, so

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in lobbyir		ry to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.	
 General issue 	area code CPT (one per page)		
H.R.2654, As H.R.2160, As	oying issues R. 1598, Patent Fairness Act of 1999, nerican Inventors Protection Act of 199 atitampering Act of 1999, nerican Inventors Protection Act of 199		
17. House(s) of C House of Rep Senate	iongress and Federal agencies contacted presentatives	☐ Check if None	
18. Name of each	individual who acted as a lobbyist in this	issue areu Covered Official Pasition (if applicabic)	New
Elkin, James			No
Drake, David			No
Casserly, Da	•		No
			_
Novartis AG	h foreign entity in the specific issues liste To the degree that public policies, eithe AG, as its parent, will benefit	d on line 16 above () Check if None इ laws or regulations, commercially benefit Novartis Corp	oration, so
Signature		Date 8/11/00	
	Bankal Kinn . Vice President		e .c 26
rinted Name and	Title Rochel King - Vice President	Page	0 () 29

Registrant Name: Novartis		
itent Name: Novartis Corporation	V.,	
OBRYING ACTIVITY. Select as many codes as necessary to ref agaged in lobbying on behalf of the client during the reporting peri- formation as requested. Attach additional page(s) as needed.	Ť	
5. General issue area code <u>ENV</u> (one per page)		
 Specific Lobbying issues S.1090/H.R. 1300; Superfund Program Completion Act of 1 H.R.1657, Children's Environmental Protection and Right: 		
·		
 House(s) of Congress and Federal agencies contacted flouse of Representatives Senate 	☐ Check if None	
18. Name of each individual who acted as a lobbyist in this issue at	Covered Official Position (if applicable)	New
Pode Posts	NAME OF THE PARTY	
Drake, David		
		No
		No.
		No
		No.
		No.
		No
19. Interest of each foreign entity in the specific issues listed on lin Novartis AG To the degree that public policies, either laws of too Novartis AG, as its parent, will benefit	or regulations, commercially benefit Novartis Cor	poration, so
19. Interest of each foreign entity in the specific issues listed on lin Novartis AG To the degree that public policies, either laws of too Novartis AG, as its parent, will benefit	or regulations, commercially benefit Novartis Cor	poration, so

Registrant Name:	Novartis		
Client Name:	Novartis Corporation	8.5%	
engaged in lobbyii	g on behalf of the client during the reporting sested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant g period. Using a separate page for each ende, provide	
16. Specific Lobl S.251, S.860, S.1155/H.R. H.R.3377, G H.R.1592, R 59 Fed. Reg. Food Quality GMO Label Juice HACC	lying issues H.R. 830, H.R. 1145, Country of Origin It 2129, National Uniformity for Food Act or enctically Engineered Food Right to Know egulatory Fairness and Openness Act of 19 60412 (11/24/96) Atrazine, Simazine and Protection Act	f 1999, " v Act,	
Departmest Environmes	Congress and Federal agencies contacted of Agriculture at Protection Agency (Administration presentatives	Check if None	
18. Name of each	individual who acted as a lobbyist in this is		New
· .	Name	Sue area Covered Official Position (if applicable)	New
Drake, Davi	Name		No
Drake, Davi	Name		No No
Drake, Davi	Name		No
Drake, Davi Muldoon, Jo Haller, Sara	Name		No No
Drake, Davi Muldoon, Jo Hailer, Sara	Name		No No No
Drake, Davi Muldoon, Jo Haller, Sara	Name		No No No
Drake, Davidoon, Jo Huller, Sara King, Rache	Name e th foreign entity in the specific issues listed to	Covered Official Position (if applicable)	No No No
Drake, Davide Muldoon, Jo Haller, Sara King, Rache	Name t t t foreign entity is the specific issues listed t To the degree that public policies, either AG, as its parent, will benefit.	Covered Official Position (if applicable)	No No No No

Regi	istrant Name:	Novartis	
Clie	nt Name:	Novartis Corporation	
enga	ged in lebbyin	IVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant g on behalf of the client during the reporting period. Using a separate page for each code, provide ested. Attach additional page(s) as needed.	
	General issue Specific Lobb H.R.1778, Fe S.746, Regula	~ (
17.	House(s) of C House of Rep Senate	ongress and Federal agencies contacted Check if None resentatives	
18.	Name of each	individual who acted as a lobbyist in this issue area	
		Name Covered Official Position (if applicable)	New
	Drake, David		
******	Drake, David King, Rachel		No
	Drake, David King, Rachel		
			No
	King, Rachel		No
	King, Rachel	h foreign entity in the specific issues listed on line 16 above Check if None	No No
Sign	King, Rachel		No No

LOBBYING ACTIVITY. Select as many codes as necessary to refl	ect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting periodic information as requested. Attach additional page(s) as needed.	- "
15. General issue area code HCR (one per page)	
 Specific Lobbying issues H.R. 4607, Medicare Prescription Drug Act of 2000, S.2807, Medicare Prescription Drug and Modernization Act 	of 2000,
17. House(s) of Congress and Federal agencies contacted Drug Enforcement Administration Food & Drug Administration House of Representatives Senate	(I) Check if Nane
• .	
18. Name of each individual who acted as a lobbyist in this issue ar	c a
Name	Covered Official Position (if applicable)
Eikin, James Bumbaugh, Deborah	
King, Rachel	
Casserly, Dan	
	~
	İ
FO . Interpret of each function autity in this amonific issues listed as limit	
19. Interest of each foreign entity in the specific issues listed on lim Novartis AG To the degree that public policies, either laws a too Novartis AG, as its parent, will benefit.	
Novartis AG To the degree that public policies, either laws a	
Novartis AG To the degree that public policies, either laws a	Date _ 8/11/00

Registrant Name: Novartis **Novartis Corporation** Client Name: Data Description Item 16 Labbying Issues Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Pediatric Studies Program Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy Bills Chairman's Mark (HELP Confidentiality Bills) Xenstransplantation Prospective Payment System Dalanced Budget Refinement Act Page 13 of 20

Reg	istrant Name:	Novartis		
Clie	ant Name:	Novartis Corporation		
eng	aged in lobbyin		y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide !.	
£5.	General issue	area code LBR (one per page)		
16.	Specific Lobb OSHA Ergor	rying issues somics Legislation		
17.	House(s) of C Department House of Reg Senate		□ Check if None	r
18.	Name of each	individual who acted as a lobbyist in this	issue area	
		Name	Covered Official Position (if applicable)	New
	Drake, David		Covered Official Position (if applicable)	New
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
	Drake, David		Covered Official Position (if applicable)	+
				+
19.				+
19.				+
19.				+
	Interest of eac	th foreign entity is the specific issues listed		No
Sign	Interest of eac	h foreign entity in the specific issues listed	d on line 16 above Check if None Date 8/11/00	No
Sign	Interest of eac	th foreign entity is the specific issues listed	d on line 16 above X Check if None	No

tegistrant Name:	Novartis		
lient Name:	Novartis Corporation		
ngaged in lobbyin		to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide	
5. General issue		•	
5. Specific Lobb H.R.3887/S, S.841 (Kenne H.R.664/S, T. H.R.2030, M H.R.1885/S, H.R.1796, M H.R.1115/S, H.R.1090, M	oying issues 2232, Medicare Wellness Act of 2000,	t of 1999, crity Act, ug Benefit Act of 1999, Extension Act of 1999, t Act of 1999,	
Department (ongress and Federal agencies contacted of Health & Human Services Administration presentatives	(2) Check if None	
QUIIATE.			
	individual who acted as a lobbyist in this i	ssue area Covered Official Position (if applicable)	New
Name of each	Name		+
Name of each	Name		No
Name of each Elkin, James Drake, David	Name		No No
Name of each Elkin, James Drake, David	Name Deborah		No No
Elkin, James Drake, David Bumbaugh, I	Name Debgrah		No No No
Elkin, James Drake, David	Name Debgrah		No No
B. Name of each Elkin, James Drake, David Bumbaugh, I	Name Debgrah		No No No No
8. Name of each Elkin, James Drake, David Bumbaugh, I	Name Debgrah		No No No No
Elkin, James Drake, David Bumbaugh, I King, Ruchel Casserly, Dau	Name Deborah In the specific issues listed	Covered Official Position (if applicable)	No No No No
8. Name of each Elkin, James Drake, David Bumbaugh, I King, Rachel Casserly, Day 9. Interest of each Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit.	Covered Official Position (if applicable) on line 16 above (i) Check if None	No No No No

Registrant Name:	Novartis		
Client Name;	Novartis Corporation		
engaged in lobbyin		o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide	
 General issue Specific Lobb 			
vi vpreme meet	A will write		
			`
a u (3 aa	because and Palandary Control of	82 74 - 1 105 ·	
/. House(s) of C	Congress and Federal agencies contacted	X Check if None	
	-		
Name of each	individual who acted as a lobbyist in this iss	itte arca	
	Name	Covered Official Position (if applicable)	New
· · · · · · · · · · · · · · · · · · ·			
rān			***************************************
			1 1
9. Interest of eac	th foreign entity in the specific issues listed o	n line 16 above 🔀 Check if None	
ienature		Date 8/11/00	
	45 1 1 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	PagePage	. 16 ac 20
rantou tvatne arju	7 ahr	Fag	e 30 01 40

Registrant Name:	Novartis	
Client Name:	Nevartis Corporation	
engaged in lobbyin	TVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant ag on behalf of the client during the reporting period. Using a separate page for each code, provide sested. Attach additional page(s) as needed.	
15. General issue		
Specific Lobb	ying issues	
F7 However of C	Congress and Federal agencies contacted K Check if None	
ir. nodsets) or c	oulgress and rederat agencies connected	
	·	
18. Name of each	individual who acted as a lobbyist in this issue area	
	Name of the state	: 1
	Name Covered Official Position (If applicable)	New
	Name Covered Official Position (if applicable)	New
	Name Covered Official Position (if applicable)	New
	Name Covered Official Position (If applicable)	New
	Name Covered Official Position (if applicable)	New
	Name Covered Official Position (if applicable)	W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	Name Covered Official Position (IF applicable)	New
		W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
		W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
19. laterest of each		W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ig. laierest of eac		W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	th foreign entity in the specific issues listed on line 16 above Check if None	W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Signature	th foreign entity in the specific issues listed on line 16 above	W 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Signature	th foreign entity in the specific issues listed on line 16 above Check if None	

General issue Specific Lob R&D Tax C	bying issues	
	Congress and Federal agencies contacted Congress and Federal agencies contacted contac	
. Name of eac	t individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable)	New
. Name of eac Drake, Davi	Name Covered Official Position (if applicable)	
	Name Covered Official Position (if applicable)	No No
Drake, <u>Davi</u>	Name Covered Official Position (if applicable)	No
Drake, Davi King, Racke	Name Covered Official Position (if applicable)	No No

Cli	ent Name: Novartis Corporation		
eng	BBYING ACTIVITY. Select as many codes as necessary aged in tobbying on behalf of the client during the reportion as requested. Attach additional page(s) as needed	ng period. Using a separate page for each code, provide	
15.	General issue area code TRD (one per page)		
16.	Specific Lobbying issues Economic Sanctions SRM Ben/BSE China/World Trade Organization Fast Track Negotiating Authority		
§ 7.	House(s) of Congress and Federal agencies contacted Department of Commerce	Check if None	
	Food & Drug Administration House of Representatives Senate		
18.	Name of each individual who acted as a lobbyist in this i	issue area Covered Official Position (if applicable)	. New
	Haller, Saruh		No
	King, Rachel		No
	7005; 045(N)		
		-	
_	——————————————————————————————————————		
			 -
19.	Interest of each foreign entity in the specific issues listed Novartis AG To the degree that public policies, either too Novartis AG, as its parent, will benefit.	t on line 16 above Check if None r laws or regulations, commercially benefit Novartis Corp	ooration, s
Sig	nature	Date	

Client Name:	Novartis Corporation		
engaged in lobbyii	fivity. Select as many codes as necessary to ng on behalf of the client during the reporting p uested. Attach additional page(s) as needed.	reflect the general issue areas in which the registrant eriod. Using a separate page for each code, provide	
	area code WAS (one per page)		
16. Specific Lobi	bying issues		
		·	
17. House(s) of 6	Congress and Federal agencies contacted	K Check if None	
	and the transfer of the transf	kd Citrol II (1900	
40 - 23			
io. Hame of each	individual who acted as a lobbyist in this issue	÷ area	
10. Harre of Cavi	nidividual who acted as a lobbyist in this issue	e area Covered Official Position (if applicable)	New
	Name		New
To trace of cave	Name	Covered Official Pasition (if applicable)	New
Table of Cavi	Name	Covered Official Pasition (if applicable)	Now
70. Traine of case	Name	Covered Official Pasition (if applicable)	New
To Train of Car	Name	Covered Official Pasition (if applicable)	New
	Name	Covered Official Pasition (if applicable)	New
	Name	Covered Official Pasition (if applicable)	New
	Name	Covered Official Pasition (if applicable)	New
AND AND AND AND AND AND AND AND AND AND	Name	Covered Official Pasition (if applicable)	New
	Name	Covered Official Pasition (if applicable)	New
	Name	Covered Official Pasition (if applicable)	New
	Name	Covered Official Position (if applicable)	New
	Natic	Covered Official Position (if applicable)	New
	Natic	Covered Official Position (if applicable)	New
19. Interest of car	Name Name Ch foreign entity in the specific issues listed on	Covered Official Position (if applicable)	
19. Interest of car	Name Name Ch foreign entity in the specific issues listed on	Covered Official Position (if applicable)	